Shots:

• Schrödinger to receive $55M upfront and is eligible to receive $2.7B as preclinical- development- regulatory & commercial milestones along with royalties on sales of each product commercialized by BMS
• Schrödinger to grant BMS exclusive WW rights to develop & commercialize the development candidates emerges from the collaboration
• The collaboration will merge Schrödinger’s computational platform & drug discovery capabilities with BMS' expertise in development & commercialization to advance small molecule therapies targeting oncology- immunology & neurological disorders. The collaboration includes two of Schrödinger’s early-stage programs and additional undisclosed targets

 ­ Ref: BusinessWire | Image: BMS